# Lilly Asia Ventures

> Lilly Asia Ventures is a VC fund backing Biotechnology and Health Care. See 221 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 221
- Last investment: Jun 2026
- Lead investor: 25%
- Fund size: $40M
- Last fund: Feb 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/eli-lilly-and-company
- Website: http://www.lillyasiaventures.com

Lilly Asia Ventures is a VC fund in Shanghai focused on Biotechnology and Health Care. Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. Lilly Asian Ventures invests in promising life science companies with strong management teams and innovative technology and/or business models. Their initial focus will be primarily on opportunities inChina, although they will consider investment opportunities elsewhere in east and south Asia.

## Contacts

5 contacts available for Lilly Asia Ventures. Shizune tracks 4 team members at Lilly Asia Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/lilly-asia-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $14M–$100M |
| Series B | $25M–$110M |
| Series C | $30M–$308M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 86 | 39% |
| Health Care | 64 | 29% |
| Medical | 47 | 21% |
| Pharmaceutical | 32 | 14% |
| Therapeutics | 25 | 11% |

34 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 53 | 24% |
| Series B | 50 | 23% |
| Series C | 30 | 14% |
| Funding Round | 13 | 6% |
| Series D | 11 | 5% |

13 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 74 | 33% |
| United States | 40 | 18% |
| Hong Kong | 3 | 1% |
| Canada | 1 | 0% |
| Israel | 1 | 0% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jiaxin Li | partner | 1 | https://shizune.co/investors/profile/jiaxin-li-815c |
| Judith Li | Partner | 11 | https://shizune.co/investors/profile/judith-li |
| Stella Shi | Venture Partner | 0 | https://shizune.co/investors/profile/stella-shi-yibin |
| Yi Shi | Managing Director & Founder | 14 | https://shizune.co/investors/profile/yi-shi-2 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NewLimit | NewLimit specializes in treating age-related diseases to extend the human health span. It works on developing epigenetic reprogramming medicines to treat diseases with large unmet needs. | $435M | Series C | Jun 02, 2026 |  |
| Accro Bioscience | Accro Bioscience research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis. | $50M | Series C | May 18, 2026 |  |
| Starna Therapeutics | Starna Therapeutics offers development of innovative drugs with RNA as the core, and has an industry-leading RNA and organ-selective delivery technology platform with independent intellectual property rights; the company has established a rich R&D pipeline , covering infectious disease vaccines, tumor immunity and other fields. | $40M | Series B | May 12, 2026 |  |
| ZSPepLib | ZSPepLib is a peptide lead drug developer, established in January 2017, coordinates Zhuzhou, Hunan. It is a platform-based company specializing in peptide lead drug discovery, focusing on the development, production, sales and new peptide drugs of the large-capacity peptide library. Screening R&D technical services. | $44.2M | Series C | May 11, 2026 |  |
| Pulnovo Medical | Pulnovo Medical integrates development, production and services. Our core products including use pf radiofrequency ablation technology to treat pulmonary hypertension. The high-frequency ablation equipment and intravascular catheters developed by the company are pioneer inventions with global invention patents. | $100M | Series D | Apr 20, 2026 |  |
| Syneron | Syneron was founded by Sinovation Ventures and is dedicated to using artificial intelligence and biotechnology to address two significant global challenges: the efficient development of novel biological therapies and the low-carbon manufacture of biochemicals. | $150M | Series B | Mar 31, 2026 |  |
| Excalipoint Therapetics | Excalipoint Therapeutics is a Private limited company. | $27.7M | Seed | Mar 18, 2026 |  |
| Stairway Medical | Stairway Medical is a developer of implantable brain-computer interface technology. | $72.6M | Venture - Series Unknown | Mar 13, 2026 |  |
| QuantX Biosciences | QuantX Biosciences is a biotechnology company that specializes in computational drug discovery and small-molecule therapeutic products. | $85M | Series B | Feb 09, 2026 |  |
| NeuShen Therapeutics | NeuShen Therapeutics is a biotechnology company trailblazing the future treatment of neurological and psychiatric disorders. |  | Series A | Jan 28, 2026 |  |

10 of 221 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 39 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 36 deals together
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund, 21 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 21 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 19 deals together
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 14 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Health Care Investors](https://shizune.co/investors/health-care-investors)
- [Health Care VC Funds](https://shizune.co/investors/health-care-vc-funds)
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)

## FAQ

### What does Lilly Asia Ventures invest in?

Lilly Asia Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 221 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Lilly Asia Ventures's check size?

Lilly Asia Ventures typically joins rounds of $14M–$100M at Series A, $25M–$110M at Series B and $30M–$308M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Lilly Asia Ventures participates in.

### How do I contact Lilly Asia Ventures?

Public channels for Lilly Asia Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Lilly Asia Ventures?

The team at Lilly Asia Ventures includes Jiaxin Li (partner), Judith Li (Partner) and Stella Shi (Venture Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co